A total of 757 patients with malignancies treated with a PD-(L)1-Ab (nivolumab, pembrolizumab, or avelumab, n = 734) or PD-(L)1-Ab/TKI (n = 23) were enrolled in this study (Fig. 1). The gene discussed is CD274; the disease is cancer.